Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Fra1 Polyclonal Antibody
Goat Polyclonal Antibody
Supplier: Invitrogen™ PA518530
Description
This antibody is predicted to react with bovine, canine, mouse, porcine and rat based on sequence homology. This antibody is tested in Peptide ELISA: antibody detection limit dilution 1,000.
The v-Fos oncogene was initially detected in two independent murine osteosarcoma virus isolates and an avian nephroblastoma virus. Members of the c-Fos gene family, including c-Fos, Fos B, Fra-1 and Fra-2, encode nuclear phosphoproteins that are rapidly and transiently induced by a variety of agents and function as transcriptional regulators for several genes. In contrast to c-Jun proteins, which form homo- and heterodimers that bind to specific DNA response elements, c-Fos proteins are only active as heterodimers with members of the Jun gene family. In addition, selected ATF/CREB family members can form leucine zipper dimers with Fos and Jun. Different dimers exhibit differential specificity and affinity for AP-1 and CRE sites.
Specifications
Fra1 | |
Polyclonal | |
Unconjugated | |
FOSL1 | |
AW538199; FOS like 1, AP-1 trancription factor subunit; FOS like 1, AP-1 transcription factor subunit; FOS like antigen 1; Fosl1; FOS-like antigen 1; FOS-like antigen-1; fos-related antigen 1; FRA; Fra1; fra-1; HGNC:13718; LOW QUALITY PROTEIN: fos-related antigen 1 | |
Goat | |
Ammonium Sulfate Precipitation | |
RUO | |
8061 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot | |
0.5 mg/mL | |
TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
P15407 | |
FOSL1 | |
Synthetic peptide sequence (QREIEELQKQKER) corresponding to the internal amino acids of FOSL1 (aa 148-161). | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction